4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24^th Annual Meeting

- Abstract on 4D-710 for cystic fibrosis lung disease accepted for oral presentation at ATS 2021 International Conference

EMERYVILLE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced preclinical data presentations from non-human primate (NHP) studies at two upcoming medical meetings, the American Society for Gene and Cell Therapy (ASGCT) 24^th Annual Meeting, held virtually from May 11 – 14 and the American Thoracic Society (ATS) 2021 International Conference, held virtually from May 14 – 19. The data presentations will address three of the company's wholly-owned product candidates leveraging three distinct targeted and evolved vectors across three therapeutic areas: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-310 for the treatment of Fabry disease and 4D-710 for the treatment of cystic fibrosis lung disease.

For the first-time, 4DMT will describe the design of 4D-150’s three distinct anti-angiogenic mechanisms and will present preclinical data demonstrating highly significant efficacy, durable aqueous anti-VEGF levels within the NHP eye, safety and tolerability in the laser-choroidal neovascularization (CNV) model.

Details for the presentations at each conference are as follows:

ASGCT 24^th Annual Meeting
Abstracts are available online and presentations and posters will be accessible through ASGCT’s website at www.asgct.org.

Abstract Title: A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates
Session Type: Oral Presentation
Session Date/Time: Wednesday May 12, 2021 5:30 PM - 7:15 PM EDT
Session Title: AAV Biology, Engineering, Immunology and Animal Modeling
Abstract number: 64

Abstract Title: A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression and Safety in Non-Human Primates
Session Type: Oral Presentation
Session Date/Time: Friday May 14, 2021 12:15 PM - 2:00 PM EDT
Session Title: Gene Therapy for Lysosomal Storage Disorders